交易中 11-18 10:59:35 美东时间
-7.170
-2.49%
Druckenmiller’s Duquesne bought a $30M SpaceX stake, halved Tesla call exposure, boosted Amazon and exited Alphabet in Q3.
今天 03:53
CNBC traders picked Micron, Digital Realty, Natera and Moody’s; Natera raised FY2026 sales guidance after strong results, while Moody’s missed estimates.
11-13 23:18
CNBC’s Final Trades featured Uber, Micron, Natera and Datadog, with analysts citing bullish views and all four stocks posting gains.
09-22 20:24
This approval supports the use of the Signatera test to guide adjuvant atezolizumab (Tecentriq®) treatment decisions in patients with MIBC. Natera expects to commercially launch Signatera for MIBC in Japan in the first
09-22 20:06
Tempus AI acquires Personalis for $1.5B to target the $20B MRD cancer monitoring market. Get full deal details and analysis.
07-22 02:52
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, and Aveta Biomics, Inc., a clinical-stage immuno-oncology company advancing first-in-class oral immunotherapies for solid tumors,
06-29 18:12
Natera won Japan approval for Signatera in colorectal cancer, paving the way for a commercial launch by 2026.
06-25 02:14
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced a major enhancement to its Panorama non-invasive prenatal test (NIPT). Powered by the company's novel
05-26 18:09
William Blair starts Natera coverage, citing MRD growth potential, strong moat, and diversified pipeline supporting long-term outlook.
04-15 02:30
Natera rises after a Delaware court grants a 30% ongoing royalty in its MRD patent battle with ArcherDx and Invitae.
04-09 20:19